HIA
NBIX icon

HFM Investment Advisors’s Neurocrine Biosciences NBIX Stock Holding History

HFM Investment Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.69K Buy
10
+5
+100% +$742 ﹤0.01% 524
2026
Q1 		$659 Hold
5
– – ﹤0.01% 562
2025
Q4 		$710 Hold
5
– – ﹤0.01% 576
2025
Q3 		$702 Hold
5
– – ﹤0.01% 513
2025
Q2 		$628 Buy
+5
New +$573 ﹤0.01% 566

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

HFM Investment Advisors's NBIX Position: Q2 2026 in Review

HFM Investment Advisors increased its Neurocrine Biosciences (NBIX) stake by 100% in Q2 2026, buying an estimated $742 and bringing the position to 10 shares worth $1.69K. The position accounts for ﹤0.01% of the portfolio, ranked #524.

HFM Investment Advisors first reported a position in NBIX in Q2 2025 and has held it in 5 quarters since. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • HFM Investment Advisors held 10 shares of Neurocrine Biosciences worth $1.69K as of Q2 2026.
  • HFM Investment Advisors bought 5 Neurocrine Biosciences shares in Q2 2026, an estimated $742.
  • Neurocrine Biosciences made up ﹤0.01% of HFM Investment Advisors's portfolio in Q2 2026, its #524 holding.
  • HFM Investment Advisors first reported a position in Neurocrine Biosciences in Q2 2025 and has held it in 5 quarters since.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on HFM Investment Advisors's 13F filing for Q2 2026, filed 4 Aug 2026.